Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Cost-effectiveness analysis of pneumococcal polysaccharide vaccination from age 60 in São Paulo State, Brazil.

Neto JT, de Araujo GT, Gagliardi A, Pinho A, Durand L, Fonseca M.

Hum Vaccin. 2011 Oct;7(10):1037-47. doi: 10.4161/hv.7.10.15987. Epub 2011 Oct 1.

2.

Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions.

Ogilvie I, Khoury AE, Cui Y, Dasbach E, Grabenstein JD, Goetghebeur M.

Vaccine. 2009 Aug 6;27(36):4891-904. doi: 10.1016/j.vaccine.2009.05.061. Epub 2009 Jun 9. Review.

PMID:
19520205
3.

Cost effectiveness of pneumococcal conjugate vaccination against acute otitis media in children: a review.

Boonacker CW, Broos PH, Sanders EA, Schilder AG, Rovers MM.

Pharmacoeconomics. 2011 Mar;29(3):199-211. doi: 10.2165/11584930-000000000-00000. Review.

PMID:
21250759
4.

The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.

Isaacman DJ, Strutton DR, Kalpas EA, Horowicz-Mehler N, Stern LS, Casciano R, Ciuryla V.

Clin Ther. 2008 Feb;30(2):341-57. doi: 10.1016/j.clinthera.2008.02.003. Review.

PMID:
18343273
5.

Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe.

Fedson DS, Nicolas-Spony L, Klemets P, van der Linden M, Marques A, Salleras L, Samson SI.

Expert Rev Vaccines. 2011 Aug;10(8):1143-67. doi: 10.1586/erv.11.99. Epub 2011 Aug 3. Review.

PMID:
21810065
6.

Advances in pneumococcal vaccines: what are the advantages for the elderly?

Vila-Córcoles A.

Drugs Aging. 2007;24(10):791-800. Review.

PMID:
17896829
7.

Evaluating the costs and benefits of pneumococcal vaccination in adults.

Porchia BR, Bonanni P, Bechini A, Bonaccorsi G, Boccalini S.

Expert Rev Vaccines. 2017 Feb;16(2):93-107. doi: 10.1080/14760584.2017.1242419. Epub 2016 Oct 12. Review.

PMID:
27680425
8.

Pneumococcal vaccination in adults: does it really work?

Pitsiou GG, Kioumis IP.

Respir Med. 2011 Dec;105(12):1776-83. doi: 10.1016/j.rmed.2011.07.008. Epub 2011 Aug 4. Review.

9.

Benefits and effectiveness of administering pneumococcal polysaccharide vaccine with seasonal influenza vaccine: an approach for policymakers.

Gilchrist SA, Nanni A, Levine O.

Am J Public Health. 2012 Apr;102(4):596-605. doi: 10.2105/AJPH.2011.300512. Epub 2012 Feb 16. Review.

10.

Estimating health service utilization for treatment of pneumococcal disease: the case of Brazil.

Sartori AM, Novaes CG, de Soárez PC, Toscano CM, Novaes HM.

Vaccine. 2013 Jul 2;31 Suppl 3:C63-71. doi: 10.1016/j.vaccine.2013.05.029. Review.

PMID:
23777694
11.

[Consensus document on pneumococcal vaccination in adults with risk underlying clinical conditions].

Picazo JJ, González-Romo F, García Rojas A, Peréz-Trallero E, Gil Gregorio P, de la Cámara R, Morató ML, Rodríguez A, Barberán J, Domínguez Hernández V, Linares Rufo M, Jimeno Sanz I, Portolés JM, Sanz Herrero F, Espinosa Arranz J, García-Sánchez V, Galindo Izquierdo M.

Rev Esp Quimioter. 2013 Sep;26(3):232-52. Spanish. No abstract available.

12.

Recommendations for the use of the 23-valent polysaccharide pneumococcal vaccine in adults: a Belgian consensus report.

Peetermans WE, Van de Vyver N, Van Laethem Y, Van Damme P, Thiry N, Trefois P, Geerts P, Schetgen M, Peleman R, Swennen B, Verhaegen J.

Acta Clin Belg. 2005 Nov-Dec;60(6):329-37. Review.

PMID:
16502593
13.

Economic evaluations of pneumococcal vaccination strategies in adults. A summary of the results.

Thiry N, Beutels P, Van Damme P.

Acta Clin Belg. 2005 Nov-Dec;60(6):338-44. Review.

PMID:
16502594
14.

Systematic review of pneumococcal disease costs and productivity loss studies in Latin America and the Caribbean.

Bahia L, Toscano CM, Takemoto ML, Araujo DV.

Vaccine. 2013 Jul 2;31 Suppl 3:C33-44. doi: 10.1016/j.vaccine.2013.05.030. Review.

PMID:
23777689
15.

Economic Evidence of Pneumococcal Vaccination in Older Adults: Uncertain Modelling or Competitive Tendering?

Garattini L, Padula A, Da Costa MR.

Pharmacoeconomics. 2016 Mar;34(3):221-4. doi: 10.1007/s40273-015-0341-4. Review. No abstract available.

PMID:
26518294
16.

Assessment of vaccine candidates for persons aged 50 and older: a review.

Eilers R, Krabbe PF, van Essen TG, Suijkerbuijk A, van Lier A, de Melker HE.

BMC Geriatr. 2013 Apr 15;13:32. doi: 10.1186/1471-2318-13-32. Review.

17.

SEPAR-ALAT Consensus Document on Antipneumoccal Vaccination in Smokers.

Jiménez Ruiz CA, Buljubasich D, Sansores R, Riesco Miranda JA, Guerreros Benavides A, Luhning S, Chatkin JM, Zabert G, de Granda Orive JI, Solano Reina S, Casas Herrera A, de Lucas Ramos P.

Arch Bronconeumol. 2015 Jul;51(7):350-4. doi: 10.1016/j.arbres.2014.12.003. Epub 2015 Jan 29. English, Spanish.

18.

Pneumococcal Vaccines--a Real World Perspective.

Swaminathan S, Balajee G.

J Assoc Physicians India. 2015 Apr;63(4 Suppl):25-8. Review. No abstract available.

PMID:
26562960

Supplemental Content

Support Center